XORTX Announces New Clinical Advisory Board Member

By Dr. Matthew Watson

CALGARY, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the Company’s clinical advisory board, Dr. Charles Edelstein.

Read this article:
XORTX Announces New Clinical Advisory Board Member

Related Post

categoriaGlobal News Feed commentoComments Off on XORTX Announces New Clinical Advisory Board Member | dataSeptember 1st, 2021


This author published 3972 posts in this site.


FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.

Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research